Moneycontrol PRO
HomeNewscoronavirusCOVID-19 crisis | Uttar Pradesh to spend up to $1 billion to buy vaccines, in talks with Pfizer, Sputnik V

COVID-19 crisis | Uttar Pradesh to spend up to $1 billion to buy vaccines, in talks with Pfizer, Sputnik V

The move by Uttar Pradesh, home to more people than Brazil, comes as many Indian states curtail vaccinations due to severe shortages amid a record surge in coronavirus infections, with India recording more than 4,000 deaths for a second straight day as its health system fails to cope.

May 13, 2021 / 18:06 IST
Source: Reuters

India's most populous state of Uttar Pradesh will spend up to $1 billion to buy COVID-19 shots and held early talks this week with companies such as Pfizer and the local distributor of Russia's Sputnik V, a state official said on Thursday.

The move by Uttar Pradesh, home to more people than Brazil, comes as many Indian states curtail vaccinations due to severe shortages amid a record surge in coronavirus infections, with India recording more than 4,000 deaths for a second straight day as its health system fails to cope.

Delhi's O2 requirement down to 582 MT, told Centre to give surplus quota to other states: Manish Sisodia

Uttar Pradesh has also held pre-bid talks with Indian vaccine companies the Serum Institute of India - licensed to make the AstraZeneca and Novavax  shots - Bharat Biotech and Cadila Healthcare as part of a global tender to buy 40 million doses over the next few months, state spokesman Navneet Sehgal told Reuters.

He said Johnson and Johnson could also confirm their participation in the tender by late Thursday via email. Sputnik V's local distributor, Dr. Reddy's Laboratories, has also held talks.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"Money is not an issue, we have a huge budget," said Sehgal, a senior bureaucrat in the state of 240 million people. "We will spend up to 100 billion rupees ($1.36 billion)." He however said funds would have to be diverted from other areas to buy the vaccines.
Reuters
first published: May 13, 2021 05:54 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347